Performance of pemetinib/pemetinib in clinical trials

Pemigatinib/Pemigatinib has demonstrated significant efficacy and safety in clinical trials. In a clinical trial called FIGHT-202, a total of 107 patients with FGFR2 fusions/rearrangements participated in the trial. After receiving pemetinib treatment, all patients experienced a certain degree of remission, which was specifically manifested as a reduction in tumor size and a reduction in complications. The results of the study showed that compared with the historical average survival time of patients with previous second- and third-line treatments, the second-line treatment with pemetinib extended the survival time of patients by more than three times. In addition, in clinical trials of pemetinib in the treatment of cholangiocarcinoma, 38% of patients experienced tumor shrinkage, effectively controlling tumor progression without serious adverse reactions.